Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Say Hello to the New Richest Person in Asia - Bloomberg

19h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
500325 RELIANCE RIGD RLNIY

10
Who Is Mukesh Ambani, Asia's Newest Richest Man?: QuickTake - Bloomberg

21h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BABA RCOM 500325 RELIANCE RIGD RIIL 532712 523445 RLNIY

0
Reliance vs PSUs: Battle for ATF pipelines in Mumbai heats up

2018-07-16 freepressjournal.in
Mumbai: The battle over lucrative pipelines supplying jet fuel to Mumbai airport is hotting up with a powerful formation of Reliance Industries and private airlines Jet Airways and Emirates trying to break the stranglehold of PSU oil firms BPCL and HPCL.
500325 RELIANCE RIGD 532617 JETAIRWAYS RLNIY

2
Few stocks rising from India selloff even as market hits record

2018-07-16 theedgemarkets
(July 16): India may be Asia’s best-performing major market this year, but not everyone is rejoicing the return of the nation’s benchmark gauges into record territory.
532540 500325 HDB 500180 RELIANCE RIGD HDFCBANK TCS TTNQY RLNIY

0
Asia has a new wealth king as Alibaba's Jack Ma is dethroned

2018-07-15 theage.com.au
Mukesh Ambani overtook Alibaba Group founder Jack Ma to become Asia's richest person as he positions Reliance Industries Ltd. to disrupt the e-commerce space in India.
500325 RELIANCE RIGD RLNIY

0
Asia has a new wealth king as Alibaba's Jack Ma is dethroned

2018-07-15 smh.com.au
Mukesh Ambani overtook Alibaba Group founder Jack Ma to become Asia's richest person as he positions Reliance Industries Ltd. to disrupt the e-commerce space in India.
500325 RELIANCE RIGD RLNIY

1
Market capitalisation of nine of top 10 most valued cos zoom Rs 1.58 lakh cr

2018-07-15 moneycontrol
Combined market capitalisation of nine of the 10 most valued companies surged by a whopping Rs 1,58,882.34 crore last week, helped by an overall strong broader market and smart surge in the valuation of Reliance Industries Ltd (RIL).
500325 KMBKY RELIANCE HINDUNILVR TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD KOTAKBANK 500696 HDFCBANK TCS 500247 RLNIY SBAZ

1
M-cap of nine of top 10 most valued firms zoom Rs 1.58 lakh cr

2018-07-15 thehindubusinessline
Over the last week, the Sensex recorded a significant rise of 883.77 points. File Photo - BusinessLine
500325 KMBKY RELIANCE HINDUNILVR TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD KOTAKBANK 500696 HDFCBANK TCS 500247 RLNIY SBAZ

1
Check out these top 10 stocks that rallied the most last week

2018-07-14 moneycontrol
The week gone by has given investors many events to cheer for with the Sensex hitting record highs and the Nifty reclaiming the 11,000 mark. Despite fears of a US-China trade war which lingers and thus forcing investors to take a cautious approach towards the equity market, individual stocks did not disappoint to make a mark.
500325 532839 RELIANCE IDBI MS.PRE HCTHY MS.PRF MS.PRG MS.PRA SHILPAMED TTNQY DISHTV 5225 532540 532187 RIGD 532281 FORTISMLR MS IHHHF 523696 RLNIY 500116 INDUSINDBK 530549 532843 MS.PRI FORTIS MS.PRK HCLTECH TCS Q0F

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

14h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

15h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 759470107